SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999; 340: 7784.
  • 2
    Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001; 93: 16331637.
  • 3
    Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001; 345: 159164.
  • 4
    Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004; 22: 10551062.
  • 5
    Goldflam K, Hunt KK, Gershenwald JE, et al. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer. 2004; 101: 19771986.
  • 6
    McDonnell SK, Schaid DJ, Myers JL, et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol. 2001; 19: 39383943.
  • 7
    Schrag D, Kuntz KM, Garber JE, Weeks JC. Benefit of prophylactic mastectomy for women with BRCA1 or BRCA2 mutations. JAMA. 2000; 283: 30703072.
  • 8
    Chung MH, Ye W, Giuliano AE. Role for sentinel lymph node dissection in the management of large (> or = 5 cm) invasive breast cancer. Ann Surg Oncol. 2001; 8: 688692.
  • 9
    Bedrosian I, Reynolds C, Mick R, et al. Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer. 2000; 88: 25402545.
  • 10
    Miner TJ, Shriver CD, Jaques DP, Maniscalco-Theberge ME, Krag DN. Sentinel lymph node biopsy for breast cancer: the role of previous biopsy on patient eligibility. Am Surg. 1999; 65: 493498; discussion 8–9.
  • 11
    Gray RJ, Forstner-Barthell AW, Pockaj BA, Schild SE, Halyard MY. Breast-conserving therapy and sentinel lymph node biopsy are feasible in cancer patients with previous implant breast augmentation. Am J Surg. 2004; 188: 122125.
  • 12
    Cohen LF, Breslin TM, Kuerer HM, Ross MI, Hunt KK, Sahin AA. Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy. Am J Surg Pathol. 2000; 24: 12661272.
  • 13
    Khan A, Sabel MS, Nees A, et al. Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy. Ann Surg Oncol. 2005; 12: 697704.
  • 14
    Breslin TM, Cohen L, Sahin A, et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2000; 18: 34803486.
  • 15
    Wilke LG, McCall LM, Posther KE, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006; 13: 491500.
  • 16
    Fleissig A, Fallowfield LJ, Langridge CI, et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat. 2006; 95: 279293.
  • 17
    Lucci A, Mackie L, Beitsch P, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection, versus SLND alone in the American College of Surgeons Oncology Group (ACOSOG) Trial Z0011. Ann Surg Oncol. 2006; 13( 2 Suppl): 4.
  • 18
    Komenaka IK, Bauer VP, Schnabel FR, et al. Allergic reactions to isosulfan blue in sentinel lymph node mapping. Breast J. 2005; 11: 7072.
  • 19
    Albo D, Wayne JD, Hunt KK, et al. Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. Am J Surg. 2001; 182: 393398.
  • 20
    Yared MA, Middleton LP, Smith TL, et al. Recommendations for sentinel lymph node processing in breast cancer. Am J Surg Pathol. 2002; 26: 377382.
  • 21
    King TA, Ganaraj A, Fey JV, et al. Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events: experience in patients undergoing prophylactic mastectomy. Cancer. 2004; 101: 926933.
  • 22
    Dupont EL, Kuhn MA, McCann C, Salud C, Spanton JL, Cox CE. The role of sentinel lymph node biopsy in women undergoing prophylactic mastectomy. Am J Surg. 2000; 180: 274277.
  • 23
    Black D, Specht M, Lee JM, et al. Detecting occult breast cancer in prophylactic mastectomies: sentinel node biopsy vs. Pre-operative MRI. Ann Surg Oncol. 2006; 13( 2 Suppl): 9.
  • 24
    Gershenwald JE, Hunt KK, Kroll SS, et al. Synchronous elective contralateral mastectomy and immediate bilateral breast reconstruction in women with early-stage breast cancer. Ann Surg Oncol. 1998; 5: 529538.
  • 25
    Alberg AJ, Singh S. Epidemiology of breast cancer in older women: implications for future healthcare. Drugs Aging. 2001; 18: 761772.
  • 26
    Adepoju LJ, Symmans WF, Babiera GV, et al. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer. 2006; 106: 4250.
  • 27
    Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004; 6: R149156.